Table 1.
Availability of medicines for diabetes and hypertension
| Medicine | Mean availability (%) of medicine | ||||
|---|---|---|---|---|---|
| Peck et al. | WHO/HAI | SARA | |||
| All facilities# | Diabetes services | Cardiovascular disease services | |||
| N = 24 | N = 107 | N = 1297 | N = 248 | N = 316 | |
| Diabetes | |||||
| Glibenclamide | 47* | 19* | 52 | ||
| Metformin | 33 | 46† | 57 | 39 | |
| Insulin | 17; 8; 8‡ | 34 | |||
| Hypertension | |||||
| Captopril 25 mg | 48 | 13 | |||
| Captopril or lisinopril | 25 | ||||
| ACE inhibitors | 24 | ||||
| Nifedipine | 33 | 57§ | |||
| Calcium channel blockers | 29 | ||||
| Atenolol 50 mg | 48 | 15 | |||
| Atenolol or propranolol | 50 | ||||
| Beta-blockers | 41 | ||||
| Hydrochlorothiazide or bendrofluazide | 33 | 31¥ | |||
FBO = Faith Based Organization; SR = sustained release formulation.
#Availability of essential tracer medicines is measured across all health facilities surveyed.
*glibenclamide 5 mg tablet.
†metformin 500 mg tablet.
‡short-acting, intermediate-acting and long-acting insulin assessed separately.
§WHO/HAI survey specified 20 mg sustained-release formulation.
¥specified as thiazide diuretics.